Shared on01 Aug 25Fair value Increased 12%
Valneva's consensus analyst price target has increased to €6.95, primarily driven by a sharp rise in future P/E despite a decline in net profit margin. What's in the News Valneva entered a development and manufacturing agreement with AGC Biologics for Phase 2 supply of its four-valent Shigella vaccine, with recent Phase 2 studies in infants and human challenge trials planned.